Abstract: The present invention relates to methods for detecting prostate cancer, methods for reliable prostate cancer grading, methods for determining the progression of prostate cancer, methods for defining advanced prostate cancer, and methods for treating prostate cancer patients based on the detection of biomarkers. In particular, the present disclosure is based on the determination that a combination of three specific endosomal biomarkers can be used to detect prostate cancer and/or determine the degree of progression of such cancer in a subject.

Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.

Abstract: Methods for detecting a prostate cancer in a subject comprise detecting a marker selected from an endosomal associated marker and/or a lysosomal associated marker from the subject.

Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.

Abstract: Methods for detecting a prostate cancer in a subject comprise detecting a marker selected from an endosomal associated marker and/or a lysosomal associated marker from the subject.

Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.

Abstract: The present disclosure relates to methods and products for imaging or labelling cells. Certain embodiments of the present disclosure provide a method of intracellular imaging of a cell. The method comprises exposing the cell to a complex comprising a phenylpyridine iridium (III) (and/or a functional derivative thereof) and a tetrazolato compound and imaging the complex in the cell.

Abstract: The present disclosure relates to complexes for intracellular imaging and also to methods and kits for intracellular imaging or cell labelling. Certain embodiments of the present disclosure provide a complex comprising a transition metal carbonyl compound, a conjugated bidentate ligand and a tetrazolato compound comprising a saccharide group.

Abstract: Methods for detecting a prostate cancer in a subject comprise detecting a marker selected from an endosomal associated marker and/or a lysosomal associated marker from the subject.

Abstract: The present disclosure relates to methods and products for labelling, binding and/or detection of lipids. Certain embodiments provide a method of labelling a lipid. The method comprises exposing the lipid to a complex comprising a transition metal carbonyl compound, a conjugated bidentate ligand and a tetrazolato compound, and thereby labelling the lipid by binding the complex to the lipid.

Abstract: The present disclosure relates to methods for detecting a prostate cancer. Certain embodiments of the present disclosure provide a method of detecting a prostate cancer in a subject, the method comprising detecting a marker selected from an endosomal associated marker and/or a lysosomal associated marker from the subject.